Primary Care Clinicians' Responses to a Hypoglycemia Risk Calculator for Diabetes Mellitus in Ambulatory Care (HG_Tool)

November 22, 2019 updated by: Michael Weiner, Indiana University
Hypoglycemia (HG) is common and can be dangerous in diabetes mellitus, so identifying patients at risk may lead to useful preventive strategies and improved quality of care and health outcomes. This study will test the implementation of a computerized alert tool for clinicians.

Study Overview

Status

Completed

Detailed Description

Diabetes mellitus is one of the most common non-communicable diseases worldwide and is a major cause of morbidity and mortality. An estimated 346 million people had diabetes in 2011, and diabetes is predicted to become the seventh leading cause of death in the world by the year 2030. In the United States, the incidence of diabetes nearly tripled between 1990 and 2010, with 1.9 million new cases diagnosed in 2010. Hypoglycemia (HG) is recognized as a limiting factor in optimal glycemic management of patients with diabetes. This potentially costly condition, occurring in approximately 20% to 60% of patients who receive oral medications for diabetes, threatens patient safety, quality of life, and potentially, cardiovascular health. Investigators have identified risk factors for HG, built a risk calculator for use by clinicians, integrated the calculator into the G3 electronic medical record system, and demonstrated our ability to collect data about outcomes. In this project, investigators studied the outcomes of implementing the risk calculator tool into clinical practice in ambulatory primary care. The findings and tools developed from this project will promote improved patient safety and medical care for diabetes.

Study Type

Interventional

Enrollment (Actual)

220

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

The study included clinicians who were scheduled to provide primary care during the four-month intervention period.

Inclusion Criteria for patients:

  • Being at least 21 years of age
  • Have been prescribed or dispensed a drug for diabetes mellitus

Exclusion Criteria for patients:

N/A

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Clinical decision support via alert tool
Clinicians received access to the electronic alert tool, which automatically displayed patients' risk of hypoglycemia.
The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
No Intervention: Usual care
Clinicians did not receive access to the electronic alert tool.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with hypoglycemia during the study period
Time Frame: Five-month follow-up period
Participants with hypoglycemia had blood glucose level less than 70 mg/dL
Five-month follow-up period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with changes to prescriptions for diabetes or antibiotics: new, refilled, changed, or discontinued
Time Frame: Five-month follow-up period
Prescriptions for insulin and sulfonylurea drugs are assessed
Five-month follow-up period

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with inpatient or outpatient medical encounters
Time Frame: Five-month follow-up period
Includes emergency encounters
Five-month follow-up period
Number of participants undergoing patient education related to diabetes
Time Frame: Five-month follow-up period
Text analysis of medical encounter notes
Five-month follow-up period
Number of A1c, glucose, and creatinine blood tests
Time Frame: Five-month follow-up period
Mean and SD
Five-month follow-up period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 14, 2016

Primary Completion (Actual)

September 30, 2016

Study Completion (Actual)

September 30, 2016

Study Registration Dates

First Submitted

November 21, 2019

First Submitted That Met QC Criteria

November 22, 2019

First Posted (Actual)

November 26, 2019

Study Record Updates

Last Update Posted (Actual)

November 26, 2019

Last Update Submitted That Met QC Criteria

November 22, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Clinical Trials on Clinical decision support via alert tool

3
Subscribe